KTTA Stock Risk & Deep Value Analysis
Pasithea Therapeutics Corp
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About KTTA Stock
We analyzed Pasithea Therapeutics Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran KTTA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is KTTA Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
High
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for KTTA?
- âš
Unfavorable clinical trial results or delays (ongoing)
- âš
Failure to secure additional funding, leading to insolvency or severe dilution (ongoing)
- âš
Increased cash burn without corresponding pipeline progress (Q1/Q2 earnings)
- âš
Heightened competition in mental health drug development
Unlock KTTA Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Pasithea Therapeutics Corp (KTTA) Do?
Market Cap
$7.38M
Sector
Healthcare
Industry
Biotechnology
Employees
4
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Visit Pasithea Therapeutics Corp WebsiteIs KTTA Stock Undervalued?
Unlock the full AI analysis for KTTA
Get the complete DVR score, risk analysis, and more
Does KTTA Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Stable
Moat Sources
1 Identified
The company's intellectual property is its primary (and only) potential moat source. However, as an early-stage biotech, the durability is entirely dependent on successful clinical trials, regulatory approvals, and commercialization, which are highly uncertain.
Moat Erosion Risks
- •Failure of clinical trials to demonstrate efficacy or safety
- •Expiration of patents or invalidation of IP claims
- •Stronger, better-funded competitors entering the same therapeutic areas with superior compounds
KTTA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive KTTA Stock Higher?
Near-Term (0-6 months)
- •Updated cash runway guidance (Q1/Q2 2026 earnings, expected May/Aug 2026)
- •Potential pre-clinical data readouts or IND filings (H1 2026)
- •New institutional investor participation (ongoing)
Medium-Term (6-18 months)
- •Initiation of Phase 1 or Phase 2 clinical trials for lead candidates (late 2026 / H1 2027)
- •Formation of strategic R&D partnerships (H2 2026 / 2027)
- •Expansion of mental health clinics network (ongoing)
Long-Term (18+ months)
- •Positive Phase 2 clinical trial results for a lead drug candidate leading to partnership/acquisition discussions (2028-2029)
- •Broader market adoption of novel mental health therapies
- •Successful monetization of IP portfolio
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for KTTA?
- ✓
Positive clinical trial data readouts (Phase 1/2 success)
- ✓
Announcements of significant non-dilutive funding or strategic partnerships
- ✓
Insider buying activity (indicating management confidence)
- ✓
Increase in institutional ownership
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for KTTA (Pasithea Therapeutics Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
